Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Date:2/20/2008

for income taxes 119.7 127.1

Depreciation (includes accelerated

depreciation) 95.6 95.6

Amortization 80.8 80.8

EBITDA 507.0 527.0

Adjusted for:

Global supply chain initiative 23.4 23.4

Share-based compensation 16.7 16.7

Licensing charges 6.0 6.0

Loss on early extinguishment of debt 1.9 1.9

Adjusted EBITDA $555.0 $575.0

The reconciliation table is based in part on management's estimate of adjusted EBITDA for the year ending December 31, 2008. Watson expects certain known GAAP charges for 2008, as presented in the schedule above. Other GAAP charges that may be excluded from estimated EBITDA are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown. These GAAP charges, such as potential asset impairment charges, are dependent upon future events and valuations that have not yet been performed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Watson Receives FDA Approval for Generic Accuneb(R)
4. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... - Bioenterprise Corporation is pleased to announce that it will ... , PEI.  Bioenterprise has established a 3-year strategic ... the commercialization of agricultural technologies and innovations. ... They have been at the heart of agri-innovation in ... Dave Smardon , President & CEO of Bioenterprise Corporation.  ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
(Date:4/16/2015)... MENLO PARK, Calif. , April 16, 2015 ... and the Company), a biopharmaceutical company focused on developing ... indications, today announced that the Mayo Clinic Cancer ... site for the ongoing, multicenter Phase I/II study of ... most common and deadly form of human brain cancer. ...
(Date:4/16/2015)... Tex. (PRWEB) April 16, 2015 ... chain management systems for highly regulated industries, is ... been name a monthly columnist for Cold Chain ... ( http://www.coldchainiq.com ). His column titled, Global Cold ... chain information for today’s life sciences, pharmaceutical and ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... a long-planned departure from its traditional focus, high-end computer ... U.S. Army for development of two different products. , ... it has secured $2.2 million in federal contracts for ... the Armys Research, Development and Engineering Command (CERDEC) to ...
... bar codes to video screens, Eau Claire-based entrepreneur Mike ... business opportunities. , ,A former technology consultant for Delta Technology ... when he founded StrandWare Inc. , a company based ... time he sold the company in 2001, it had expanded ...
... International, Inc. , which makes the drug Hectorol, reported $2.5 ... quarter ended March 31. , ,Hectorol is a Vitamin D-based ... in patients with chronic kidney disease. Gross margins run about ... profitability from the same quarter last year, when it reported ...
Cached Biology Technology:SLE of Eau Claire lands $2.2 million in federal contracts 2SLE of Eau Claire lands $2.2 million in federal contracts 3Online Kiosks founder Mike Strand uses contest to screen new business plan 2Online Kiosks founder Mike Strand uses contest to screen new business plan 3
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... human gut may not just be helping digest food but ... metabolic functions of other organs, like the liver, according to ... . These findings offer new understanding of the symbiotic relationship ... the microbiota can impact overall health. "The gut microbiota ...
... of Maryland School of Medicine researchers have identified two ... to new, more effective treatments for excessive alcohol drinking. ... brain, GABA receptors and toll-like receptor 4 (TLR4), "caused ... rodents that had been bred and trained to drink ...
... North America have been awarded Leopold Leadership Fellowships ... Woods Institute for the Environment, the Leopold Leadership ... scientists make their knowledge accessible to decision makers. ... 20 mid-career academic environmental researchers as fellows. They ...
Cached Biology News:Gut bacteria can control organ functions 2University of Maryland School of Medicine study identifies genes associated with binge drinking 2University of Maryland School of Medicine study identifies genes associated with binge drinking 3University of Maryland School of Medicine study identifies genes associated with binge drinking 420 researchers selected as 2011 Leopold Leadership Fellows 220 researchers selected as 2011 Leopold Leadership Fellows 320 researchers selected as 2011 Leopold Leadership Fellows 4